The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH

Q1 Biochemistry, Genetics and Molecular Biology

Advances in biological regulation Pub Date : 2024-05-01 DOI:10.1016/j.jbior.2024.101032

Melchiorre Cervello , Giuseppa Augello , Lucio Cocco , Stefano Ratti , Matilde Y. Follo , Alberto M. Martelli , Antonella Cusimano , Giuseppe Montalto , James A. McCubrey

{"title":"The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH","authors":"Melchiorre Cervello , Giuseppa Augello , Lucio Cocco , Stefano Ratti , Matilde Y. Follo , Alberto M. Martelli , Antonella Cusimano , Giuseppe Montalto , James A. McCubrey","doi":"10.1016/j.jbior.2024.101032","DOIUrl":null,"url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is a common cancer which unfortunately has poor outcomes. Common anti-cancer treatments such as chemotherapy and targeted therapy have not increased patient survival significantly. A common treatment for HCC patients is transplantation, however, it has limitations and complications. Novel approaches are necessary to more effectively treat HCC patients. Berberine (BBR) is a nutraceutical derived from various fruits and trees, which has been used for centuries in traditional medicine to treat various diseases such as diabetes and inflammation. More recently, the anti-proliferation effects of BBR have been investigated in the treatment of patients with various cancers, especially colorectal cancer, and in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In this review, we will focus on studies with BBR in liver diseases.</p></div>","PeriodicalId":7214,"journal":{"name":"Advances in biological regulation","volume":"92 ","pages":"Article 101032"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in biological regulation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212492624000204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) is a common cancer which unfortunately has poor outcomes. Common anti-cancer treatments such as chemotherapy and targeted therapy have not increased patient survival significantly. A common treatment for HCC patients is transplantation, however, it has limitations and complications. Novel approaches are necessary to more effectively treat HCC patients. Berberine (BBR) is a nutraceutical derived from various fruits and trees, which has been used for centuries in traditional medicine to treat various diseases such as diabetes and inflammation. More recently, the anti-proliferation effects of BBR have been investigated in the treatment of patients with various cancers, especially colorectal cancer, and in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In this review, we will focus on studies with BBR in liver diseases.

查看原文本刊更多论文

营养保健品小檗碱在治疗肝细胞癌和其他肝病（如非酒精性脂肪肝和非酒精性脂肪性肝病）方面的潜力。

肝细胞癌（HCC）是一种常见的癌症，不幸的是，它的治疗效果很差。化疗和靶向治疗等常见抗癌疗法并没有显著提高患者的生存率。肝细胞癌患者的常见治疗方法是移植，但这种方法存在局限性和并发症。有必要采用新方法来更有效地治疗 HCC 患者。小檗碱（BBR）是一种从各种水果和树木中提取的营养保健品，几个世纪以来一直被传统医学用于治疗糖尿病和炎症等各种疾病。最近，人们研究了小檗碱在治疗各种癌症（尤其是结直肠癌）以及非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）中的抗增殖作用。在本综述中，我们将重点讨论 BBR 治疗肝病的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊